OR WAIT null SECS
September 02, 2019
Innovation in manufacturing technologies must occur to ensure the availability of gene therapies and cell therapies.
August 29, 2019
While downgrading the impact of nitrosamine impurities on patients, FDA vows to step up investigations for other drug types.
August 02, 2019
A design strategy can ensure conflicting properties are managed appropriately for multi-API controlled-release formulations.
Rapid change towards industry developing and manufacturing niche APIs is leading to smaller-scale facilities that offer higher containment and flexibility.
August 01, 2019
Pharmaceutical Technology spoke with Anil Kane, executive director, global science and technology, pharmaceutical development services, at Thermo Fisher Scientific about the industry’s need for more capacity in the manufacture of highly potent APIs.
Does the pharmaceutical industry have adequate access to contained equipment, facilities, and infrastructure for the manufacture of highly potent APIs?
July 02, 2019
Nanotechnology is enabling enhanced bioavailability, improved stability, and targeted delivery of challenging APIs.
June 02, 2019
Excipients and new processing techniques can make a real difference in the development of highly potent therapies.
May 03, 2019
Automated candle and pressure-plate filtration equipment for removing catalyst residues from API slurries are operated in a closed system.
April 02, 2019
Confidence in the quality systems and scientific competence of the API manufacturing team is essential.